Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.
Ingen-Housz-Oro S, Amatore F, El Aarbaoui T, de Masson A, Pham-Ledard A, Dereure O, Quereux G, Faiz S, de Vicq de Cumptich M, Ram-Wolff C, Janela-Lapert R, Guenova E, Lheure C, Le Corre Y, Adamski H, Bonnet N, Grange F, Troin L, Tzoumpa S, Bagot M, Beylot-Barry M
British Journal of DermatologyIn the feed 23 Jul 2026, issue 2026 Aug 18, added to PubMed 23 Jul 2026
Topics: Skin cancer & tumorsCutaneous lymphomaCancer drugs
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42490360 · DOI 10.1093/bjd/ljag211